<DOC>
	<DOCNO>NCT01690377</DOCNO>
	<brief_summary>Dendritic cell ( DCs ) professional antigen-presenting cell immune system . As currently use clinical vaccination protocol cancer patient , immunological clinical response observe . Several subset dendritic cell characterize peripheral blood . One subset refer plasmacytoid dendritic cell ( PDC ) , another myeloid dendritic cell ( myDC ) . To date PDC myDC evaluate capability induce anti-tumor immune response patient . For reason investigator perform safety efficacy study PDC myDC stage IV melanoma patient .</brief_summary>
	<brief_title>Natural Dendritic Cell Vaccines Metastatic Melanoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Stage IV melanoma accord 2001 AJCC criterion . Limited tumor burden ; LDH &lt; 2x upper limit normal Histological proof cutaneous melanoma Melanoma express tyrosinase and/or gp100 ( approximately 20 % cell determine immunohistochemistry stain ) HLA Type A2 WBC &gt; 3.0 * 10E9/l , lymphocytes &gt; 0.8 * 10E9/l , platelet &gt; 100 * 10E9/l , serum creatinine &lt; 150 umol/l , serum bilirubin &lt; 25 umol/l , normal liver function Expected adequacy follow Written inform consent autoimmune disorder , concomitant use immunosuppressive drug serious concomitant disease , serious active infection , malignancy past 5 year exception curatively treat carcinoma insitu cervix/squamous cell carcinoma skin know allergy shell fish ( vaccine contains KLH ) pregnancy lactation clinical sign CNS metastasis , patient clinical suspicion CNS metastasis , CT scan brain perform exclude prior chemotherapy , immunotherapy , radiotherapy within three month plan vaccination allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Dendritic Cells</keyword>
</DOC>